For many years much of the medical and public health communities have anxiously awaited the long-overdue federal Controlled Substances Act reclassification of marijuana to characterize it more accurately.
In 2022, Biden requested the Health and Human Services Administration to conduct an extensive evaluation of marijuana’s medical benefits and risks. As part of the evaluation, the U.S. Food and Drug Administration determined that marijuana has legitimate medical benefits and relatively low toxicity. The resulting 2023 HHS report concluded marijuana’s reclassification from a Schedule I to a less restrictive Schedule III was appropriate. Now, the Biden administration announced a formal rulemaking process by the Department of Justice for the reclassification by the Drug Enforcement Administration.
H/T: www.usatoday.com
